24.3.2023 20:42:34 CET | Monsenso |
Selskabsmeddelelse
Selskabsmeddelelse nr. 09-2023
København den 24.marts 2023
Bestyrelsen i Monsenso A/S offentliggør hermed beslutningen om at udstede warrants til medarbejdere, herunder direktion, der er i uopsagt stilling og som var ansat 1. januar 2023.
Warrants modnes over 36 måneder fra 1.maj 2023 til 30. april 2026, men kun såfremt modtageren stadig er ansat i selskabet. Ikke udnyttede warrants bortfalder 31.august 2030. Der er tildelt DKK 840.000 warrants, der giver ret til tegning af nominelt DKK 84.000 aktier i selskabet.
Bestyrelsen har fastsat udnyttelseskursen til DKK 0,22 per warrant, hvilket er mindre end markedskursen og i overensstemmelse med § 5.3 i selskabets vedtægter.
Warrantmodtageren skal ikke betale vederlag for at tegne warrants. De modnede warrants kan udnyttes 2 gange om året efter offentliggørelse af selskabets års- og halvårsrapport i et udnyttelsesvindue på p.t. 2 uger.
Monsenso’s aktiekapital udgør nominelt DKK 3.050.211,10 fordelt på 30.502.111 styk aktier a DKK 0,10.
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til:
Selskabet:
CEOThomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
BestyrelsesformandPeter Mørch EriksenTlf. +45 51 99 66 00E-mail: petermorcheriksen@outlook.com
Certified Adviser:
Norden CEF A/SJohn NordenE-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning for mentale lidelser. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen af psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
24.3.2023 20:42:34 CET | Monsenso |
Company Announcement
Company announcement no. 09-2023
Copenhagen, 2023.03.24
The Board of Directors of Monsenso A/S hereby announces the decision to issues warrants for employees and management, who are in a non-terminated position and who were employed on 1 January 2023.
Vesting period for the warrants is 36 months from 1 May 2023 to 30 April 2026, but only if the recipient is still employed by the company. Unexercised warrants expire on 31 August 2030. DKK 840,000 warrants have been granted, giving the right to subscribe for a nominal DKK 84,000 shares in the company.
The Board of Directors has set the exercise price at DKK 0.22 per warrant, which is less than the market price and in accordance with § 5.3 of the company’s articles of association.
The warrant holder shall not pay any compensation for the granting of the warrants. The vested warrants can be exercised twice a year after publication of the company’s annual and half-yearly report in an exercise window of pt. 2 weeks.
Monsenso’s share capital amounts to a nominal value of DKK 3,050,211.10 divided into 30,502,111 shares of DKK 0.10.
Any inquiries regarding this notice should be directed to:
Monsenso
CEOThomas LethenborgTel +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenTel +45 51 99 66 00E-mail: Petermorcheriksen@outlook.com
Certified Adviser
Norden CEF A/SJohn Norden
E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
